TSX:BCT - CA1079302081 - Common Stock
The current stock price of BCT.CA is 10.69 CAD. In the past month the price decreased by -89.42%. In the past year, price decreased by -99.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 425.87M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 343.98M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 266.82M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 204.61M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 103.88M | ||
WLLW.CA | WILLOW BIOSCIENCES INC | N/A | 97.56M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 90.92M | ||
BLU.CA | BLUENERGIES LTD | N/A | 82.42M | ||
NRX.CA | NUREXONE BIOLOGIC INC | N/A | 66.41M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 18.46 | 65.81M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 60.21M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 45.90M |
Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William Williams
Employees: 17
Phone: 16049211810
The current stock price of BCT.CA is 10.69 CAD. The price increased by 5.84% in the last trading session.
The exchange symbol of BRIACELL THERAPEUTICS CORP is BCT and it is listed on the Toronto Stock Exchange exchange.
BCT.CA stock is listed on the Toronto Stock Exchange exchange.
BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 20.10M CAD. This makes BCT.CA a Nano Cap stock.
BRIACELL THERAPEUTICS CORP (BCT.CA) currently has 17 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BCT.CA does not pay a dividend.
BRIACELL THERAPEUTICS CORP (BCT.CA) will report earnings on 2025-10-27, after the market close.
BRIACELL THERAPEUTICS CORP (BCT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-60.57).
ChartMill assigns a fundamental rating of 2 / 10 to BCT.CA. While BCT.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -60.57. The EPS decreased by -693.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -123.71% | ||
ROE | -321.51% | ||
Debt/Equity | 0 |